Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Dechra announces “groundbreaking” strangles vaccine
"We are sure that the new strangles vaccine will be a vital tool in disease prevention and a huge benefit to the equestrian industry" - Sara Barker, Dechra.

Protein-based tool is available for horses and ponies.

Dechra Veterinary Products has announced a "groundbreaking" vaccine to protect horses and ponies against strangles.

Developed over 25 years, Strangvac is the first and only intramuscular vaccine for strangles - a highly contagious disease caused by the Streptococcus equi bacterium.

The new vaccine contains recombinant proteins from Streptococcus equi and features DIVA (Differentiating Infected from Vaccinated Animals) capability. It possesses no live bacteria or bacterial DNA, nor will it trigger a positive result in PCR or culture tests.

Strangvac is proven effective in more than 94 per cent of horses, reducing the clinical signs of strangles, including high temperature, coughing. Difficulty swallowing and inappetance. It can be administered to foals from the age of five months, with two injections given at a four-week interval.

The manufacturer states that horses at high risk of Streptococcus equi should be re-vaccinated after two months, such as those in livery. Immunological memory was found in horses following repeated vaccination six months after primary vaccination.

Strangvac has been made possible thanks to more than €20million of funding from the Animal Health Trust and, more recently, the Swedish company Intervacc AB. 

Dr Andrew Waller, chief scientific officer at Intervacc AB, the company that developed the vaccine, comments: “Strangvac is a groundbreaking new vaccine which, alongside good stable management and biosecurity procedures, can play a really important role in improving herd immunity and reducing the number of strangles cases in the equine population, thereby preventing major economic loss to the equestrian industry.”

Sara Barker, equine field support manager at Dechra, added: “Strangles is highly contagious and is one of the most common equine respiratory diseases with an estimated 600 outbreaks each year in the UK alone. Feared by horse owners due to the potential severity of clinical signs and the infectious nature of strangles, we are sure that the new strangles vaccine will be a vital tool in disease prevention and a huge benefit to the equestrian industry as a whole.”

Further information about the vaccine is available from Dechra territory sales managers.

Become a member or log in to add this story to your CPD history

Animal Medicines Amnesty returns this November

News Story 1
 Veterinary practices are being urged to help owners safely dispose of any unused and expired pet medicines - not just antibiotics - during November's Animal Medicines Amnesty.

Organised by the Responsible Use of Medicines Alliance Companion Animal and Equine (RUMA CA&E), the initative is supported by a range of cross-sector organisations.

Practices are encouraged to use the campaign to engage the whole practice team and raise awareness of the safe disposal of medicines with clients. Learn how your practice can get involved at rumacae.org.uk 

Click here for more...
News Shorts
APHA launches free virtual work experience programme

The Animal and Plant Health Agency (APHA), in collaboration with Springpod, has launched a free virtual work experience programme, giving young people across the UK the chance to explore careers dedicated to protecting animal and plant health.

The on-demand programme offers a unique insight into career opportunities within APHA, showcasing how students can contribute to tackling some of the UK's most critical biosecurity and environmental challenges.

Designed for students aged 13 and over, the course includes more than 10 hours of engaging content featuring real-life industry insights, scenario-based challenges, and practical guidance on applying for jobs. To register for the course, visit the APHA website.